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Background: Growing evidence support a link between key components of the complement 
system and risk of venous thromboembolism (VTE). However, it remains uncertain whether 
activation of the complement system, assessed by the soluble terminal C5b-9 complement 
complex (plasma TCC), is associated with future risk of incident VTE. 
Aims: To investigate the association between plasma levels of TCC and future risk of 
incident VTE in a nested case-control study, and to explore genetic variants associated with 
plasma levels of TCC using protein quantitative trait loci (pQTL) analysis of exome 
sequencing data.  
Methods: The study population consisted of 415 VTE cases and 848 age- and sex-matched 
controls who were sampled from a population-based cohort, the Tromsø study. Logistic 
regression models were used to calculate odds ratios (ORs) with 95% confidence intervals 
(CIs) for VTE across quartiles of plasma levels of TCC. Whole exome sequencing was 
conducted in a subgroup (355 VTE patients and 354 controls) using the Agilent SureSelect 
50Mb capture kit. 
Results: The risk of VTE increased across quartiles of plasma TCC levels, particularly for 
unprovoked VTE (p for trend 0.03). Participants with plasma TCC in the highest quartile 
(>1.40 CAU/mL) had an OR for unprovoked VTE of 1.83 (95% CI 1.02-3.38) compared to 
those with plasma TCC in the lowest quartile (≤0.80 CAU/mL) in analyses adjusted for age, 
sex and body mass index. The OR for VTE by high plasma TCC was substantially higher in 
individuals with short time between blood sampling and VTE event. We found no significant 
association between genome-wide and complement-related gene variants and plasma levels of 
TCC.   
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Conclusions: Our findings showed that plasma levels of TCC are independent of gene 
regulation and that high levels of plasma TCC are associated with VTE risk, and unprovoked 
events in particular.  
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 It is not known whether complement activation, assessed by plasma levels of TCC, is 
associated with VTE 
 Genome-wide and complement-related gene variants were not associated with plasma 
levels of TCC 
 High plasma levels of TCC were associated with future risk of VTE, particularly 
unprovoked events 






Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) and 
pulmonary embolism (PE). VTE is a complex disease, affecting 1-2 per 1000 individuals 
annually (1, 2), with serious short- and long-term complications, including recurrence and 
death (3, 4). The incidence of VTE has slightly increased during the last two decades (5, 6), 
and it is likely that the incidence will continue to rise since the prevalence of major risk 
factors for VTE, such as high age, obesity and cancer, are increasing in the population (7-9). 
VTE has become a major challenge to public health and healthcare systems due to frequent 
hospitalizations, monitoring of treatment to avoid bleeding complications, severe 
complications and a high mortality rate after 30 days (10). It is therefore pivotal to identify 
novel biomarkers and unravel underlying disease mechanisms of VTE in order to facilitate 
targeted prevention and treatment.  
 
The complement system is an important part of the innate immune system organized in a 
cascade of proteolytic serine proteases with a number of biological functions (11). Growing 
evidence from observational and animal studies suggest that the complement system is 
involved in the early steps of the pathogenesis of VTE, consistent with an extensive cross-talk 
between the complement and hemostatic systems (12). Complement factor C3 is an acute-
phase reactant and a central component in activation of the complement system (13). In a 
large population-based cohort, subjects with plasma complement C3 levels in the highest 
tertile had a 58% higher risk of VTE than those in the lowest tertile, and the risk estimate 
declined to 31% after further adjustment for C-reactive protein (CRP) and body mass index 





Activation of any of the three complement pathways merge at C3 which subsequently 
activates C5 and the terminal complement pathway with final formation of C5a and the 
terminal C5b-9 complement complex (TCC) (15). The TCC exists in two forms, surface-
bound C5b-9 forming the membrane attack complex, and a soluble form where C5b-9 binds 
to S-protein and clusterin and becomes non-lytic (16).  Soluble TCC is generally accepted as a 
marker of in vivo complement activation and can be measured in plasma (17, 18). 
 
No previous study has, to the best of our knowledge, investigated the association between 
plasma levels of TCC and future risk of VTE in individuals recruited from the general 
population. Therefore, the aims of the present study were; (i) to investigate whether plasma 
levels of TCC were associated with incident VTE in a nested case-control study, (ii) to 
explore whether genetic variants were associated with plasma levels of TCC using protein 
quantitative trait loci (pQTL) analysis of exome sequencing data, and (iii) investigate whether 







The Tromsø Study is a single-center, population-based cohort, with repeated health surveys of 
inhabitants of Tromsø, Norway. All inhabitants aged ≥25 years living in the municipality of 
Tromsø, Norway were invited to participate in the fourth survey, conducted in 1994/95. A 
total of 27,158 subjects participated (77% of those invited), and were followed from the date 
of inclusion until an incident VTE, migration, death, or end of follow-up (September 1, 2007). 
All first lifetime VTE events were identified using the hospital discharge diagnosis registry, 
the autopsy registry and the radiology procedure registry at the University Hospital of North 
Norway (UNN), which is the sole hospital in the Tromsø region. Trained personnel 
adjudicated and recorded each VTE by extensive review of medical records. A VTE was 
confirmed if presence of signs and symptoms of PE or DVT were combined with objective 
confirmation by radiological procedures (i.e. compression ultrasonography, venography, 
spiral computed tomography, perfusion-ventilation scan, pulmonary angiography) or autopsy, 
and resulted in treatment initiation (unless contraindications were specified) as previously 
described (19). A VTE occurring in the presence of one or more provoking factors was 
classified as provoked. The following were regarded as provoking factors: surgery or trauma 
(within eight weeks before the event), acute medical conditions (acute myocardial infarction, 
acute ischemic stroke, acute infections), immobilization (bed rest> 3 days or confinement to 
wheelchair within the last 8 weeks, or long distance travel ≥4 hours within the last 14 days), 
or other factor specifically described as provoking by a physician in the medical record (e.g. 
intravascular catheter). 
 
During the follow-up period (1994-2007), 462 individuals experienced a VTE event. For each 
case, two age- and sex-matched controls, who were alive at the index date of the VTE event, 
were randomly sampled from the source cohort (n=924). In total, 47 cases and 76 controls did 
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not have available plasma samples of sufficient quality for the analyses. Thus, our final nested 
case-control study consisted of 415 cases and 848 controls.   
 
Baseline Measurements 
Height (to the nearest cm) and weight (to the nearest 0.5 kg) were measured in participants 
wearing light clothing and no shoes. Body mass index (BMI) was calculated as weight 
divided by the square of height in meters (kg/m2). A self-administered questionnaire was used 
to collect detailed baseline information on smoking status and previous cardiovascular events 
(stroke, angina pectoris, TIA, and MI). 
 
Blood and DNA samples  
Non-fasting blood was collected from an antecubital vein into 5 mL vacutainers (Becton 
Dickinson, Meylan Cedex, France) containing EDTA (K3-EDTA 40µL, 0.37mol/L per tube) 
as an anticoagulant. Platelet poor plasma (PPP) was prepared by centrifugation at 3000xg for 
10 minutes at room temperature, after which the supernatant was transferred into cryovials 
(Greiner laboratechnik, Nürtringen, Germany) in 1 mL aliquots and stored at -80°C until 
further analysis. DNA isolated from blood was stored at the National CONOR Biobank (20).  
 
Exome sequencing 
Whole exome sequencing at high-coverage (≈100x) was conducted in a subgroup of the study 
population (355 VTE patients and 354 control subjects) using the Agilent SureSelect 50Mb 
capture kit. The resulting genotypes were effectively filtered (21) and imputations were 





Measurement of the soluble Terminal Complement Complex  
Plasma samples were thawed on crushed ice, and plasma levels of TCC were measured using 
an in-house enzyme-linked immunosorbent assay (ELISA) as described previously (23). In 
brief, ELISA plates (Nunc, Immunoplate II, Copenhagen, Denmark) were coated with the 
monoclonal antibody, aE11 specific for a neoantigen exposed in C9 after activation and 
incorporation into TCC, the poly (C9) unit of the TCC. Biotinylated anti-C6 monoclonal 
antibody (9C4) was used as detection antibody and Streptavidin horseradish peroxidase (GE 
Healtcare UK) was added as the final step. Optical density was measured at 405 nm 
(Dynatech MR580, Dynatech Laboratories Inc., Alexandria, Va., USA). Results are given in 
Complement Arbitrary Units (CAU)/mL. 
 
Statistical analysis 
Statistical analyses were carried out using R version 3.4.4 (The R Foundation for Statistical 
Computing c/o Institute for Statistics and Mathematics, Vienna, Austria). Plasma TCC was 
categorized according to quartile cut offs in the control population (≤0.80, 0.80-1.04, 1.04-
1.40, >1.40 CAU/ml). Means and proportions of baseline characteristics across categories of 
TCC were calculated using descriptive statistics. Logistic regression models were used to 
calculate odds ratios (OR) for VTE with 95% confidence intervals (CI) according to quartiles 
of TCC adjusted for age, sex and BMI. We did not adjust for CRP since CRP is likely to be in 
the causal pathway of complement activation and VTE. The lowest quartile of TCC was used 
as the reference group. We also calculated the P value for linear trend of ORs across 
increasing quartiles of TCC.  
 
As the follow-up time in the source cohort was long (more than 12 years for many persons), 
the results based on baseline TCC measurements could be influenced by regression dilution 
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bias. To investigate this, we performed analyses where we restricted the maximum time from 
blood sampling in Tromsø 4 to the VTE events, while keeping all controls in the analyses. 
The logistic regression analyses on time restrictions were set to require at least 10 VTE 
events, and ORs were generated at every 0.1 year increase in time since blood sampling and 
plotted as a function of this maximum time. 
 
The 1.034.910 genome-wide variants derived from the whole-exome-sequencing were used to 
investigate whether plasma TCC was regulated by any alternative genetic variants. This pQTL 
analysis was performed both in a genome-wide setting, and restricted to the loci within ±500 
kb of the different genes involved in the complement system (Supplementary Table 1). To 
adjust for multiple testing, the commonly used significance threshold of 5x10-8 was used in 
the genome-wide setting. As the cis analysis in total contained 11.806 variants, a Bonferroni-
based adjustment for multiple testing corresponded to a significance threshold of 0.05/11.806 
= 4.23x10-6. The plasma TCC values were transformed to follow a perfect standard normal 
distribution before entering the QTL analysis. The QTL analysis was done by the EPACTS 
(Efficient and Parallelizable Association Container Toolbox) software (24). The EMMAX 
(Efficient Mixed Model Association eXpedited) (25) test within EPACTS was used, which 
uses a mixed model to test for associations between a quantitative trait (TCC in this study) 







The distribution of baseline characteristics across quartiles of plasma TCC is shown in Table 
1. The mean age, sex distribution, and mean BMI were essentially similar across quartiles of 
plasma TCC. The proportion of subjects with a history of cardiovascular disease was slightly 
lower and the proportion of smokers higher in the lowest TCC quartile. Plasma levels of 
hsCRP increased as expected across quartiles of TCC from 1.32±1.08mg/L in the lowest 
quartile to 1.96±1.65mg/L in the highest quartile.  
 
The characteristics of the VTE patients are shown in Table 2. The mean age at the time of 
VTE was 67.4 years, and 48.4% of the cases were men. In total, 37.8% of the VTE events 
were PEs and 62.2% were DVTs, and 42.2% of the cases were unprovoked. The most 
common provoking factors were surgery/trauma (22.4%) and active cancer (21.4%). 
 
The ORs of VTE across quartiles of plasma TCC levels are shown in Table 3. For overall 
VTE, the OR increased across quartiles of plasma TCC (p for trend: 0.06), and subjects with 
plasma TCC >1.40 CAU/ml had a 35% higher risk of VTE compared to those with TCC 
≤0.80 CAU/ml (OR 1.35; 95% CI: 0.97-1.88).  In subgroup analyses restricted to unprovoked 
VTE, the OR for the upper (>1.40 CAU/ml) versus the lower quartile of plasma TCC (≤0.80 
CAU/ml) was 1.74 (95% CI: 1.10-2.78), and there was a statistically significant linear trend in 
the ORs across increasing quartiles of TCC (p for trend: 0.02). When restricting the analysis 
to provoked VTE, no difference in risk estimates of VTE across quartiles of TCC was 
observed. Further adjustment for BMI did not influence the estimates (Table 3). To consider 
the possibility of underestimating ORs due to regression dilution bias, we estimated ORs for 
VTE among subjects with high (highest quartile) versus low (lowest quartile) plasma TCC as 
a function of time between blood sampling and the VTE events (Figure 1). The OR for VTE 
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by high plasma TCC was substantially higher with shortened time between the blood 
sampling and the VTE events.  
 
The ORs for DVT and PE across quartiles of plasma TCC are shown in Table 4. The OR for 
DVT increased across quartiles of plasma TCC (p for trend: 0.06). Subjects with plasma TCC 
values >1.40 CAU/ml had a 38% higher risk of DVT compared to those with TCC ≤0.80 
CAU/ml (OR 1.38; 95% CI: 0.93-2.06). Although not statistically significant, the OR of 
unprovoked PE was higher in subjects with plasma TCC in the highest quartile compared to 
those in the lowest quartile (OR:1.58, 95% CI: 0.82-3.10). The estimates did not change after 
adjustment for BMI (Table 4). The ORs for DVT and PE, respectively, among subjects with 
high (highest quartile) versus low (lowest quartile) plasma TCC as a function of time between 
blood sampling and VTE were then calculated (Figure 2). The ORs for DVT and PE showed 
essentially similar patterns as the ORs for overall VTE (Figure 1, left panel), and increased 
substantially with shortened time between blood sampling and the respective events. 
 
To identify genetic variation associated with plasma levels of TCC, we tested for association 
between genome-wide and complement-related variants and plasma levels of TCC. Figure 3 
shows a modified Manhattan plot based on the results of the pQTL analysis with the genome-
wide variants marked by grey circles and the complement-related analysis (variants within 
±500 kb of the genes involved in the complement system) marked by blue triangles. Age, sex, 
BMI, and VTE status were included as covariates in the models. No gene variant had a p 
value that was statistically significant neither in the genome-wide nor in the complement-





We investigated the association between complement activation, assessed by plasma levels of 
TCC, and future risk of VTE in a population-based nested case-control study. The risk of 
VTE increased across quartiles of plasma TCC, and subjects with plasma TCC  >1.40 
CAU/ml (highest quartile) had a 35% higher risk of overall VTE and 74% higher risk of 
unprovoked VTE compared to those with TCC ≤0.80 CAU/ml (lowest quartile). The ORs for 
VTE by plasma TCC increased substantially with shortened time between blood sampling and 
the VTE events. Further, we found no significant association between genome-wide and 
complement-related gene variants and plasma levels of TCC.  Our findings indicate that 
plasma levels of TCC are independent of gene regulation, and that high levels of plasma TCC 
are associated with VTE risk, and unprovoked events in particular. 
 
A few studies have investigated the link between complement factors and the risk of VTE. In 
a large population-based cohort (the Copenhagen General Population Study), 80 517 Danes 
were followed on average 4.9 years in which 1176 developed VTE. Subjects with plasma 
complement C3 levels in the highest tertile had a 58% higher risk of VTE compared to those 
in lowest tertile, which declined to 31% higher risk of VTE after additional adjustment for 
CRP and BMI (14). Even though the risk estimate was attenuated by adjustment for CRP and 
BMI, the remaining risk and the pivotal role of complement C3 (14), may suggest that 
complement C3 is not merely a marker, but a mediator of VTE risk.   The latter concept is 
supported by experiments in C3- and C5-deficient mice which had a lower incidence of VTE 
and reduced thrombus size compared to wild-type mice in a tissue factor (TF)-dependent 
model of flow restriction-induced VTE (26). Recently, we reported that high activity of the 
classical complement pathway was associated with unprovoked VTE in a small case-control 
study (27). Furthermore, systemic lupus erythematosus (SLE) patients with a history of VTE 
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had increased deposition of C1q, C3, and C4d on platelets compared to SLE patients without 
VTE, suggesting that activation of the classical pathway of the complement system may play 
a role in the pathogenesis of VTE in SLE patients (28). The authors speculated that the effect 
was mediated by formation of TCC at the surface membrane of platelets. Accordingly, we 
found that soluble TCC, the end stage of complement activation, measured in plasma was 
associated with increased risk of VTE, and especially unprovoked VTE. In contrast to plasma 
TCC and other activation products, which directly reflect complement activation, plasma 
levels of individual complement components like C3 is not a reliable indicator of the degree 
of complement activation in vivo. Thus, our study strongly support the concept that the degree 
of complement activation, and not merely concentrations of parent molecules per se, is related 
to future risk of VTE.   
 
Our study is, to the best of our knowledge, the first to provide actual evidence for an 
association between complement activation, assessed by plasma TCC, and future risk of VTE.  
In prospective studies, the biomarker levels are usually measured at the time of inclusion and 
related to an outcome that occur several years later.  Plasma levels of modifiable biomarkers 
are expected to change over time. Fluctuations in exposure during follow-up will lead to a 
phenomenon called regression dilution bias (29), which results in an underestimation of the 
true association between exposure and outcome.  Accordingly, we found that the risk of VTE 
by plasma levels of TCC declined substantially with time between blood sampling and VTE.  
 
In our study, genome-wide and complement-related gene variants showed no significant 
association with plasma levels of TCC. These findings strongly suggest that the plasma levels 
of TCC are determined by environmental rather than genetic factors.  Autopsy- and imaging 
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studies indicate that venous thrombi originate in the valvular sinuses of large veins. The 
milieu in the valvular sinuses is characterized by severe hypoxia and stasis (30, 31), 
conditions known to induce cellular immune responses. As the complement system is 
activated by hypoxic cells and tissues (32), it is reasonable to assume that complement is also 
activated in the hypoxic milieu in the valvular sinuses. It may be speculated that subjects 
susceptible to VTE exhibit a certain pathophysiological milieu in the valvular sinuses which 
makes them prone to complement activation and thereby development of VTE. Alternatively, 
other inflammatory conditions associated with increased plasma levels of TCC (33, 34) may 
be differentially distributed between subjects who will and will not develop VTE.  However, 
because the inflammatory response, in our study assessed by plasma C-reactive protein (CRP) 
levels, secondary to such conditions would be in the causal pathway between plasma TCC and 
VTE risk, it would be methodological incorrect to adjust for plasma CRP levels in the 
statistical analyses. In fact, complement activation is upstream of inflammatory responses 
such as CRP formation (35), but when CRP is produced and bound to surfaces it is able to 
activate the classical pathway of the complement system (36, 37). 
 
A clear temporal sequence between exposure and outcome, such as in our nested case-control 
study, is a prerequisite to establish plasma levels of TCC as a risk factor of VTE. 
Circumstantial evidence support the concept that complement activation, assessed by plasma 
TCC, may be a mediator of VTE risk through platelet- and coagulation activation since it 
reflects the degree of membrane inserted C5b-9. First, incorporation of the C5b-9-complex 
into the cell membrane activates platelets and results in (i) the exposure of negatively charged 
phosphatidylserine (PS) (38) which may assembly and amplify coagulation reactions (39), (ii) 
the formation of procoagulant microvesicles (MVs) (40) which is associated with risk of VTE 
(41), and (iii) secretion of procoagulant granules from the cytoplasm of platelets (42).  
16 
 
Second, the complement system has direct procoagulant activities, including the ability to 
cleave and activate coagulation factors (44) and increase TF expression in various cell types 
(43, 44). In addition, C5a has the ability to upregulate the synthesis and release of 
plasminogen activator inhibitor-1 (PAI-1), the main endogenous inhibitor of the fibrinolytic 
system, from mast cells and basophils (43), which will further shift the prothrombotic-
antithrombotic balance in favor of a prothrombotic condition (44). 
 
Strengths of our study include the recruitment of VTE patients from a population-based 
cohort and age- and sex-matched apparently healthy controls from the same source 
population. It is a large prospective study, with robust measurements of plasma TCC. The fact 
that blood samples were collected before VTE makes it possible to make assumptions on the 
direction of the association between exposure (complement activation) and outcome (VTE). 
Some limitations of the study need to be considered. The blood samples, in which the analysis 
of plasma TCC was conducted, were drawn in 1994/95 and stored at -80°C for up to 22 years. 
The long storage time could potentially affect the plasma levels of TCC. However, it is 
unlikely that this would change the results, as this storage-effect would be similar in all 
samples. Additionally, plasma TCC was only measured at baseline, and changes in TCC 
levels during up to 12 years of follow-up could result in underestimation of the true 
association (45). Accordingly, we found that the ORs for VTE by plasma TCC decreased 
substantially with prolonged time between blood sampling and the VTE events. Finally, 
plasma TCC is a very stable activation product compared to upstream activation products 
(23). Plasma levels of TCC remains unchanged after several freezing and thawing cycles (23) 




In conclusion, results from our nested case-control study imply that complement activation, 
assessed by plasma levels of TCC, is associated with increased risk of VTE, and unprovoked 
events in particular. Genome-wide and complement-related gene variants were not associated 
with plasma levels of TCC, suggesting that local or systemic environmental factors are the 
dominating determinants of complement activation leading to increased plasma TCC. 
Functional studies are warranted to investigate the molecular mechanisms behind the 
association between plasma TCC and VTE risk.  
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Tables and figures 
 
Table 1: Characteristics across quartiles of plasma levels of the terminal complement 
complex (TCC)  









Age, years 58.7±13.5 61.3±12.8 61.4±14.0 59.8±14.4 
Sex, % men (n) 50.8 (159) 48.1 (143) 42.2 (136) 48.0 (159) 
BMI, kg/m2 26.3±4.2 26.6±4.0 26.2±4.3 26.6±4.4 
hsCRP, mg/L  1.32±1.08 1.50±1.28 1.71±1.30 1.96±1.65 
CVD* 13.7 (43) 17.5 (52) 16.1 (52) 15.1 (50) 
Daily smoking 34.2 (107) 30.3 (90) 32.9 (106) 27.5 (91) 







Table 2: Characteristics of the VTE events (n=415) 
 % (n) 
Age at VTE (years) 67.4±13.6 
Sex (males) 48.4 (201) 
Deep vein thrombosis 62.2 (258) 
Pulmonary embolism 37.8 (157) 
Unprovoked VTE 42.2 (175) 
Provoked VTE 57.8 (240) 
 Surgery/Trauma 22.4 (93) 
 Active cancer 21.4 (89) 
 Acute medical condition 15.4 (64) 
 Immobilization 17.8 (74) 




Table 3. Odds ratios (OR) with 95% confidence intervals (CI) for venous thromboembolism 




Controls Cases Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
All VTE     
≤0.80 220 93 Ref Ref 
0.80-1.04 204 93 1.08 (0.76-1.53) 1.06 (0.75-1.51) 
1.04-1.40 213 109 1.22 (0.87-1.71) 1.23 (0.88-1.73) 
>1.40 211 120 1.35 (0.97-1.88) 1.33 (0.96-1.86) 
p for trend   0.06 0.06 
Per 1 SD increase  848 415 1.09 (0.97-1.22) 1.08 (0.97-1.22) 
Unprovoked VTE     
≤0.80 220 35 Ref Ref 
0.80-1.04 204 39 1.23 (0.75-2.02) 1.17 (0.71-1.94) 
1.04-1.40 213 43 1.31 (0.81-2.15) 1.34 (0.82-2.19) 
>1.40 211 58 1.74 (1.10-2.78) 1.72 (1.08-2.75) 
p for trend   0.02 0.02 
Per 1 SD increase 848 175 1.13 (0.99-1.29) 1.13 (0.99-1.29) 
Provoked VTE     
≤0.80 220 58 Ref Ref 
0.80-1.04 204 54 0.99 (0.65-1.51) 0.98 (0.64-1.49) 
1.04-1.40 213 66 1.17 (0.78-1.74) 1.15 (0.77-1.73) 
>1.40 211 62 1.11 (0.74-1.67) 1.11 (0.74-1.67) 
p for trend   0.47 0.47 
Per 1 SD increase 848 240 1.03 (0.88-1.19) 1.04 (0.88-1.20) 
Model 1: adjusted for age and sex 





Table 4. Odds ratios (OR) with 95% confidence intervals (CI) for deep vein thrombosis 
(DVT) and pulmonary embolism (PE) according to quartiles of plasma levels of the terminal 
complement complex (TCC) 
Quartiles of   
plasma TCC 
(CAU/ml) 
Controls Cases Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
All DVT     
≤0.80 220 56 Ref Ref 
0.80-1.04 204 55 1.07 (0.70-1.62) 1.04 (0.68-1.58) 
1.04-1.40 213 73 1.36 (0.91-2.02) 1.34 (0.90-2.00) 
>1.40 211 74 1.38 (0.93-2.06) 1.36 (0.91-2.02) 
p for trend   0.06 0.07 
Per 1 SD increase 848 258 1.05 (0.90-1.20) 1.05 (0.90-1.21) 
Unprovoked DVT     
≤0.80 220 19 Ref Ref 
0.80-1.04 204 22 1.28 (0.67-2.46) 1.22 (0.64-2.34) 
1.04-1.40 213 28 1.58 (0.86-2.96) 1.59 (0.86-2.99) 
>1.40 211 34 1.87 (1.05-3.45) 1.83 (1.02-3.38) 
p for trend   0.03 0.03 
Per 1 SD increase 848 103 1.05 (0.84-1.25) 1.06 (0.85-1.26) 
Provoked DVT     
≤0.80 220 37 Ref Ref 
0.80-1.04 204 33 0.95 (0.57-1.59) 0.93 (0.56-1.55) 
1.04-1.40 213 45 1.25 (0.78-2.02) 1.22 (0.75-1.97) 
>1.40 211 40 1.12 (0.69-1.83) 1.12 (0.69-1.82) 
p for trend   0.43 0.45 
Per 1 SD increase 848 155 1.04 (0.86-1.22) 1.04 (0.86-1.22) 
All PE     
≤0.80 220 37 Ref Ref 
0.80-1.04 204 38 1.10 (0.67-1.80) 1.07 (0.65-1.77) 
1.04-1.40 213 36 1.01 (0.61-1.66) 1.04 (0.62-1.71) 
>1.40 211 46 1.30 (0.81-2.09) 1.33 (0.82-2.15) 
p for trend   0.35 0.28 
Per 1 SD increase 848 157 1.12 (0.97-1.28) 1.12 (0.98-1.28) 
Unprovoked PE     
≤0.80 220 16 Ref Ref 
0.80-1.04 204 17 1.16 (0.57-2.39) 1.10 (0.54-2.27) 
1.04-1.40 213 15 0.99 (0.47-2.08) 1.00 (0.48-2.10) 
>1.40 211 24 1.58 (0.82-3.10) 1.60 (0.83-3.15) 
p for trend   0.23 0.20 
Per 1 SD increase 848 72 1.19 (1.01-1.37) 1.19 (1.01-1.37) 
Provoked PE     
≤0.80 220 21 Ref Ref 
0.80-1.04 204 21 1.05 (0.55-1.99) 1.02 (0.54-1.95) 
1.04-1.40 213 21 1.01 (0.53-1.92) 1.03 (0.54-1.97) 
>1.40 211 22 1.09 (0.58-2.05) 1.12 (0.59-2.11) 
p for trend   0.83 0.74 
Per 1 SD increase 848 85 1.02 (0.77-1.25) 1.03 (0.78-1.26) 
Model 1: adjusted for age and sex 









Figure 1: Plots of estimated OR for VTE as a function of time from blood sampling in Tromsø 4 
(1994-95) and the VTE event (all, provoked and unprovoked events) in analyses adjusted for age, sex 









Figure 2: Plots of estimated OR for DVT and PE as a function of time from blood sampling in 
Tromsø 4 (1994-95) and event in analyses adjusted for age, sex and BMI. Large, solid circles indicate 














Figure 3: Modified Manhattan plot of QTL analysis results. The upper, dashed horizontal line 
indicates the 5x108 P value significance threshold. As the cis analysis has 11.806 variants being tested, 
a strict Bonferroni-based control for multiple testing translates to a cis significance threshold 
of− log10 0.00000423 = 5.37. This is indicated by the lower, dotted horizontal line in the figure. The 






Supplementary Table 1. Overview of the genes used in the quantitative trait loci (QTL) analysis when 
restricting the variants to loci within ±500 kb of the different genes involved in the complement system. 
 
 
Name  Main task   Pathway (mainly)  
 
Gene  
C1q Binds antigene:antibody 
complex and pathogens  
Klassisk  C1QA,B,C 
Mannose binding 
lectin (MBL)  
Binds mannose on e.g. 
bacteria    
MBL Mbl2 
C1r Activating enzyme Klassisk  C1R 
C1s Activating enzyme Klassisk C1S 
C2b Activating enzyme Klassisk  C2 
Bb Activating enzyme Alternativ CFB 
D Activating enzyme Alternativ  CFD 
MASP-1 Activating enzyme MBL MASP-1 
MASP-2 Activating enzyme MBL MASP-2 
C3  Sentral protein  All C3 
C5 Sentral protein All C5 
C4 Sentral protein All C4A,B 
C4b Binds to membranes and 
marks them for immune cells   
All  
C3b  Binds to membranes and 
marks them for immune cells   
All  
C5b Protein in the TCC  All C5 
C6 Protein in the TCC  All C6 
C7 Protein in the TCC  All C7 
C8 Protein in the TCC  All C8,A,B,G 
C9 Protein in the TCC  All C9 
CR1 Receptor for complement 
proteins  
All CR1 
CR2 Receptor for complement 
proteins  
All CR2 
CR3 Receptor for complement 
proteins  
All ITGB2 
CR4 Receptor for complement 
proteins  
All ITGAX 
C1qR Receptor for complement 
proteins  
All CD93 
C1INH One of the main regulators of 
the complement system  
Alle SERPING1 
C4bp Regulator All  
MCP (CD46) Regulator All CD46 
DAF Regulator All CD55 
H Regulator All CFH 
I Regulator All CFI 
P Regulator All  
CD59 Regulator All CD59 
CPN  Regulator  All CPN1 
